Latest news with #Galadari
Khaleej Times
12-03-2025
- Automotive
- Khaleej Times
Lynk & Co forms partnership with Galadari Brothers in UAE market
Galadari Brothers has partnered with Lynk & Co to introduce innovative vehicle line-up to the UAE market. With this strategic move, Galadari Motors becomes the official distributor of Lynk & Co vehicles across the UAE, further enhancing its diverse mobility portfolio. Lynk & Co, a premium automotive brand under the newly formed Zeekr Group, is known for its cutting-edge design, advanced technology, and high-performance vehicles. With a strong focus on innovation, the brand offers a seamless driving experience tailored to modern consumers in the UAE. Mohammed Galadari, Co-Chairman and Group CEO of Galadari Brothers, said: 'Lynk & Co represents the future of urban mobility, blending performance, technology, and sustainability in a way that resonates with the modern driver. This partnership aligns perfectly with our vision to offer premium, high-quality mobility brands that meet the evolving needs of our customers. We are proud to introduce Lynk & Co to the UAE and are confident it will redefine the local automotive landscape.' Tian Jinjun, VP of Zeekr International & Managing Director of Zeekr MEA region, said: 'In partnership with our esteemed UAE strategic partner, Galadari Brothers, we are committed to transforming this dynamic market into a regional powerhouse — serving as a center for brand marketing, professional training, spare parts distribution, and services.' Lynk & Co will introduce a range of vehicles to the UAE, including PHEV and ICE SUVs. In 2025, Lynk & Co will introduce 4 SUV models (01, 05, 06, and 09) and two sedans (03, 03+). In the future, the brand also plans to launch its first PHEV model, the Lynk & Co 08, further diversifying its model offerings. Lynk & Co's expansion into the UAE is part of its broader expansion strategy in the Mena region. With established operations in Kuwait, Saudi Arabia, Oman, and Qatar, the brand continues to strengthen its regional footprint. By leveraging Galadari's deep market expertise and strong distribution network, Lynk & Co aims to become a key player in the UAE's premium automotive market, offering vehicles that cater to the diverse needs of local consumers. Together, Galadari and Lynk & Co will continue to push the boundaries of the UAE automotive industry, delivering exceptional value and driving innovation across the market. Galadari is enhancing its customer experience by opening three state-of-the-art showrooms, each with integrated service facilities during this year. The network will continue to expand, reaching a total of five showrooms across the UAE within three years.
Zawya
10-02-2025
- Business
- Zawya
Daewoong Pharmaceutical, a leading healthcare company in Korea, has launched its botulinum toxin product NABOTA in Saudi Arabia
SEOUL, South Korea and RIYADH, Saudi Arabia /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee), a leading healthcare company in Korea, announced the official launch of its high-purity, high-quality botulinum toxin product, NABOTA, in Saudi Arabia. The launch follows a rigorous quality evaluation process conducted by the Saudi Food and Drug Authority (SFDA). As recognized with approvals from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada, Daewoong Pharmaceutical's botulinum toxin has demonstrated outstanding quality and safety. This milestone is expected to serve as a key gateway for Daewoong Pharmaceutical's expansion into the Middle Eastern market. Leveraging NABOTA's superior quality and safety, Daewoong Pharmaceutical aims to meet the needs of patients in Saudi Arabia and the wider Middle Eastern region while expanding its market share. Daewoong Pharmaceutical's premium high-purity botulinum toxin, produced using the patented 'HI-PURE™ Technology' and advanced vacuum drying processes, received FDA approval in 2019, making it the first Asian-manufactured botulinum toxin to gain such recognition. NABOTA boasts a high-purity composition with over 98% of the 900kDa complex and ensures rapid and precise effect. Additionally, its drying process prevents the formation of ice nuclei, minimizing the formation of inactive toxins, which contributes to immunogenicity and ultimately, enhancing safety. NABOTA shares the same molecular structure (900kDa) as AbbVie's Botox, which holds the largest market share in Saudi Arabia, and has demonstrated equivalent(non-inferior) efficacy, positioning NABOTA for smooth transition and accelerated market adoption in the region. To commemorate the launch, Daewoong Pharmaceutical hosted a symposium on January 24 at the Fairmont Hotel in Riyadh, Saudi Arabia. The event gathered approximately 300 local healthcare professionals and featured Dr. Hassan Galadari, a key opinion leader in the region and dermatologist from the UAE. Dr. Galadari delivered a presentation titled 'CHANGE THE GAME Prabotulinum Toxin,' sharing global clinical results and treatment insights of NABOTA to local healthcare professionals. "NABOTA has the same protein molecular structure as Botox, at 900kDa, and has proven its efficacy and safety through clinical trials and regulatory approvals in advanced markets," said Dr. Galadari. "It stands out for its precision, longevity, and high patient satisfaction." Dr. Amr Abduljabbar, a Saudi Arabian dermatologist and symposium moderator, added, "This event allowed us to share valuable insights into NABOTA's advanced manufacturing process, superior quality, and global clinical data. I believe NABOTA will be a game-changer in Saudi Arabia, a key market within the Middle East and Africa botulinum toxin industry." Jun-soo Yun, Head of the NABOTA Business Unit at Daewoong Pharmaceutical, stated, "NABOTA is Korea's most exported botulinum toxin product, owing to its high purity and quality. Daewoong Pharmaceutical's botulinum toxin products are currently approved in 69 countries and partnered in over 80 countries. Saudi Arabia is the largest market in the Middle East, and with this launch, Daewoong Pharmaceutical will further strengthen its presence in the Middle East and Africa."
